Christophe Jean
Director/Board Member at RHYTHM PHARMACEUTICALS, INC.
Net worth: - $ as of 30/03/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Hunter Smith | M | 56 | 7 years | |
Armelle Cuvillier | M | - |
B Cell Design SAS
B Cell Design SAS Miscellaneous Commercial ServicesCommercial Services B Cell Design SAS provides pharmaceutical services. It offers research and development services in producing antibodies. The firm serves as a platform for other diagnostic and pharmaceutical companies addressed to academic laboratories and industrial research. The company was founded in December 7, 2007 and is headquartered in Limoges, France. | - |
David Meeker | M | 69 | 9 years | |
Michael Kloss | M | 57 |
eureKING SA
eureKING SA Financial ConglomeratesFinance eureKING SA is a special purpose acquisition company, which engages in acquiring one or more companies or operating businesses, through a merger, capital stock exchange, share purchase, asset acquisition, reorganization or similar transaction. It focuses on the completion of an initial business combination with one or several target businesses and companies with principal operations in the biomanufacturing sector. The company was founded by Michael Kloss, Hubert Olivier, Gerard Le Fur, Christophe Jean, Alexandre Mouradian, and Rodolphe Besserve and is headquartered in Paris, France. | - |
Gaël Champier | M | - |
B Cell Design SAS
B Cell Design SAS Miscellaneous Commercial ServicesCommercial Services B Cell Design SAS provides pharmaceutical services. It offers research and development services in producing antibodies. The firm serves as a platform for other diagnostic and pharmaceutical companies addressed to academic laboratories and industrial research. The company was founded in December 7, 2007 and is headquartered in Limoges, France. | - |
Hubert Olivier | M | 64 |
Back to Basics, Inc.
Back to Basics, Inc. Food RetailRetail Trade Back to Basics, Inc. is an American company that is currently open for business. The private company prioritizes the safety of their staff and their families, especially those who are in high-risk groups. Customers are required to wear masks when entering the store.
eureKING SA
eureKING SA Financial ConglomeratesFinance eureKING SA is a special purpose acquisition company, which engages in acquiring one or more companies or operating businesses, through a merger, capital stock exchange, share purchase, asset acquisition, reorganization or similar transaction. It focuses on the completion of an initial business combination with one or several target businesses and companies with principal operations in the biomanufacturing sector. The company was founded by Michael Kloss, Hubert Olivier, Gerard Le Fur, Christophe Jean, Alexandre Mouradian, and Rodolphe Besserve and is headquartered in Paris, France. | - |
Alexandre Mouradian | M | 54 |
eureKING SA
eureKING SA Financial ConglomeratesFinance eureKING SA is a special purpose acquisition company, which engages in acquiring one or more companies or operating businesses, through a merger, capital stock exchange, share purchase, asset acquisition, reorganization or similar transaction. It focuses on the completion of an initial business combination with one or several target businesses and companies with principal operations in the biomanufacturing sector. The company was founded by Michael Kloss, Hubert Olivier, Gerard Le Fur, Christophe Jean, Alexandre Mouradian, and Rodolphe Besserve and is headquartered in Paris, France. | - |
Pascale Augé | M | 53 |
eureKING SA
eureKING SA Financial ConglomeratesFinance eureKING SA is a special purpose acquisition company, which engages in acquiring one or more companies or operating businesses, through a merger, capital stock exchange, share purchase, asset acquisition, reorganization or similar transaction. It focuses on the completion of an initial business combination with one or several target businesses and companies with principal operations in the biomanufacturing sector. The company was founded by Michael Kloss, Hubert Olivier, Gerard Le Fur, Christophe Jean, Alexandre Mouradian, and Rodolphe Besserve and is headquartered in Paris, France. | 2 years |
Rodolphe Besserve | M | 51 |
eureKING SA
eureKING SA Financial ConglomeratesFinance eureKING SA is a special purpose acquisition company, which engages in acquiring one or more companies or operating businesses, through a merger, capital stock exchange, share purchase, asset acquisition, reorganization or similar transaction. It focuses on the completion of an initial business combination with one or several target businesses and companies with principal operations in the biomanufacturing sector. The company was founded by Michael Kloss, Hubert Olivier, Gerard Le Fur, Christophe Jean, Alexandre Mouradian, and Rodolphe Besserve and is headquartered in Paris, France. | - |
Aymeric Le Chatelier | M | 55 | 10 years | |
David Connolly | M | - | 5 years | |
Gérard Le Fur | M | 73 |
eureKING SA
eureKING SA Financial ConglomeratesFinance eureKING SA is a special purpose acquisition company, which engages in acquiring one or more companies or operating businesses, through a merger, capital stock exchange, share purchase, asset acquisition, reorganization or similar transaction. It focuses on the completion of an initial business combination with one or several target businesses and companies with principal operations in the biomanufacturing sector. The company was founded by Michael Kloss, Hubert Olivier, Gerard Le Fur, Christophe Jean, Alexandre Mouradian, and Rodolphe Besserve and is headquartered in Paris, France. | - |
Stuart Arbuckle | M | 58 | 5 years | |
Bénédicte Garbil | F | 42 |
eureKING SA
eureKING SA Financial ConglomeratesFinance eureKING SA is a special purpose acquisition company, which engages in acquiring one or more companies or operating businesses, through a merger, capital stock exchange, share purchase, asset acquisition, reorganization or similar transaction. It focuses on the completion of an initial business combination with one or several target businesses and companies with principal operations in the biomanufacturing sector. The company was founded by Michael Kloss, Hubert Olivier, Gerard Le Fur, Christophe Jean, Alexandre Mouradian, and Rodolphe Besserve and is headquartered in Paris, France. | 2 years |
Lily Geidelberg | M | 32 |
eureKING SA
eureKING SA Financial ConglomeratesFinance eureKING SA is a special purpose acquisition company, which engages in acquiring one or more companies or operating businesses, through a merger, capital stock exchange, share purchase, asset acquisition, reorganization or similar transaction. It focuses on the completion of an initial business combination with one or several target businesses and companies with principal operations in the biomanufacturing sector. The company was founded by Michael Kloss, Hubert Olivier, Gerard Le Fur, Christophe Jean, Alexandre Mouradian, and Rodolphe Besserve and is headquartered in Paris, France. | 2 years |
Jennifer Good | F | 59 | 5 years | |
Piet Wigerinck | M | 58 | 6 years | |
Dana Washburn | M | 61 | 2 years | |
Margaret Liu | M | 66 | 7 years | |
Camille Bedrosian | M | 71 | 4 years | |
Lynn Tetrault | F | 61 | 4 years | |
Marc M. P. de Garidel | M | 66 | 14 years | |
Carri Duncan | M | - |
eureKING SA
eureKING SA Financial ConglomeratesFinance eureKING SA is a special purpose acquisition company, which engages in acquiring one or more companies or operating businesses, through a merger, capital stock exchange, share purchase, asset acquisition, reorganization or similar transaction. It focuses on the completion of an initial business combination with one or several target businesses and companies with principal operations in the biomanufacturing sector. The company was founded by Michael Kloss, Hubert Olivier, Gerard Le Fur, Christophe Jean, Alexandre Mouradian, and Rodolphe Besserve and is headquartered in Paris, France. | 2 years |
Eduardo Bravo Fernández de Araoz | M | 58 |
European Biopharmaceutical Enterprises
European Biopharmaceutical Enterprises BiotechnologyHealth Technology European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium. | - |
Michèle Ollier | M | 65 | 9 years | |
Anne-Marieke Ezendam | F | 56 |
eureKING SA
eureKING SA Financial ConglomeratesFinance eureKING SA is a special purpose acquisition company, which engages in acquiring one or more companies or operating businesses, through a merger, capital stock exchange, share purchase, asset acquisition, reorganization or similar transaction. It focuses on the completion of an initial business combination with one or several target businesses and companies with principal operations in the biomanufacturing sector. The company was founded by Michael Kloss, Hubert Olivier, Gerard Le Fur, Christophe Jean, Alexandre Mouradian, and Rodolphe Besserve and is headquartered in Paris, France. | 2 years |
David McGirr | M | 69 | 9 years | |
Ed Mathers Mathers | M | 64 | 11 years | |
Barbara Freischem | F | - |
European Biopharmaceutical Enterprises
European Biopharmaceutical Enterprises BiotechnologyHealth Technology European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium. | - |
Eric Halioua | M | - |
European Biopharmaceutical Enterprises
European Biopharmaceutical Enterprises BiotechnologyHealth Technology European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium. | - |
Bertrand Louvet | M | 86 |
B Cell Design SAS
B Cell Design SAS Miscellaneous Commercial ServicesCommercial Services B Cell Design SAS provides pharmaceutical services. It offers research and development services in producing antibodies. The firm serves as a platform for other diagnostic and pharmaceutical companies addressed to academic laboratories and industrial research. The company was founded in December 7, 2007 and is headquartered in Limoges, France. | - |
Pierre Levi | M | 69 |
B Cell Design SAS
B Cell Design SAS Miscellaneous Commercial ServicesCommercial Services B Cell Design SAS provides pharmaceutical services. It offers research and development services in producing antibodies. The firm serves as a platform for other diagnostic and pharmaceutical companies addressed to academic laboratories and industrial research. The company was founded in December 7, 2007 and is headquartered in Limoges, France. | - |
Elisabeth Crönert-Bendell | M | - | 3 years | |
Kristin Thompson | M | 41 |
eureKING SA
eureKING SA Financial ConglomeratesFinance eureKING SA is a special purpose acquisition company, which engages in acquiring one or more companies or operating businesses, through a merger, capital stock exchange, share purchase, asset acquisition, reorganization or similar transaction. It focuses on the completion of an initial business combination with one or several target businesses and companies with principal operations in the biomanufacturing sector. The company was founded by Michael Kloss, Hubert Olivier, Gerard Le Fur, Christophe Jean, Alexandre Mouradian, and Rodolphe Besserve and is headquartered in Paris, France. | 2 years |
Stefan Berchtold | M | - |
eureKING SA
eureKING SA Financial ConglomeratesFinance eureKING SA is a special purpose acquisition company, which engages in acquiring one or more companies or operating businesses, through a merger, capital stock exchange, share purchase, asset acquisition, reorganization or similar transaction. It focuses on the completion of an initial business combination with one or several target businesses and companies with principal operations in the biomanufacturing sector. The company was founded by Michael Kloss, Hubert Olivier, Gerard Le Fur, Christophe Jean, Alexandre Mouradian, and Rodolphe Besserve and is headquartered in Paris, France. | - |
Peter Eckenberg | M | - |
eureKING SA
eureKING SA Financial ConglomeratesFinance eureKING SA is a special purpose acquisition company, which engages in acquiring one or more companies or operating businesses, through a merger, capital stock exchange, share purchase, asset acquisition, reorganization or similar transaction. It focuses on the completion of an initial business combination with one or several target businesses and companies with principal operations in the biomanufacturing sector. The company was founded by Michael Kloss, Hubert Olivier, Gerard Le Fur, Christophe Jean, Alexandre Mouradian, and Rodolphe Besserve and is headquartered in Paris, France. | - |
Pamela Cramer | F | 50 | 3 years | |
Antoine Flochel | M | 59 | 19 years | |
Piers John Morgan | M | 57 |
European Biopharmaceutical Enterprises
European Biopharmaceutical Enterprises BiotechnologyHealth Technology European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium. | - |
Jim Flaherty | M | - | 5 years | |
Joseph Shulman | M | 49 | 4 years | |
Carol Xueref | F | 67 | 12 years | |
Yann Mazabraud | M | 51 | 4 years | |
Aidan Murphy | M | 58 | 6 years | |
François-Maurice Garnier | M | 62 | 9 years | |
Annick Schwebig | M | 73 |
B Cell Design SAS
B Cell Design SAS Miscellaneous Commercial ServicesCommercial Services B Cell Design SAS provides pharmaceutical services. It offers research and development services in producing antibodies. The firm serves as a platform for other diagnostic and pharmaceutical companies addressed to academic laboratories and industrial research. The company was founded in December 7, 2007 and is headquartered in Limoges, France. | - |
Regis Mulot | M | 58 | 6 years | |
Jennifer Chien | F | 49 | 4 years | |
Henri Beaufour | M | 59 | 19 years | |
Alain Aragues | M | - |
European Biopharmaceutical Enterprises
European Biopharmaceutical Enterprises BiotechnologyHealth Technology European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium. | - |
Christopher German | M | 53 | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Keith Gottesdiener | M | 70 | 9 years | |
Bart Henderson | M | 65 | 9 years | |
Paul Sekhri | M | 65 |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | 5 years |
Jean-Luc Bélingard | M | 74 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 8 years |
Martha Heitzmann-Crawford | M | 56 | 3 years | |
Hélène Auriol-Potier | F | 61 | 4 years | |
Pierre Kemula | M | 50 | 6 years | |
William John Jenkins | M | 77 |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | - |
Hervé Couffin | M | 72 | 13 years | |
David S. Schilansky | M | 48 | 5 years | |
David Meek | M | 59 | 3 years | |
Claire Giraut | F | 67 | 8 years | |
Sonia Benhamida | M | - | 7 years | |
Carol Stuckley | F | 68 | 4 years | |
Todd Foley | M | 52 | 7 years | |
Andrew Grethlein | M | 59 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 7 years |
Pierre Martinet | M | 74 | 13 years | |
Sotirios G. Stergiopoulos | M | 52 | 2 years | |
William Roberts | M | 45 | 2 years | |
Stéphane Durant des Aulnois | M | - | - | |
Siham Imani | F | 47 | 6 years | |
Christy Oi | F | - | 4 years | |
Dominique Laymand | F | 69 | - | |
Thomas Gidoin | M | 41 | 3 years | |
Dominique Bery | F | 53 | 5 years | |
Jean Fabre | M | 65 | 9 years | |
Philippe Robert-Gorsse | M | 63 | 11 years | |
Eugenia Litz | F | - | - | |
Heather White | F | - | - | |
Benoit Hennion | M | 48 | - | |
Ian Weatherhead | M | - | - | |
Richard A. King | M | 59 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 2 years |
Stéphane Bessette | M | 58 | - | |
Ernest Loumaye | M | 71 | - | |
Ivana Magovcevic-Liebisch | M | 55 | 2 years | |
Richard B. Love | M | 62 | 4 years | |
Michael Astrue | M | 67 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 1 years |
Thomas Wiggans | M | 72 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 1 years |
Argeris Karabelas | M | 71 |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | 2 years |
Gérard Hauser | M | 81 | 9 years | |
Frédéric Babin | M | - | - | |
Claude Bertrand | M | 61 | 8 years | |
Gérard Picot | M | 70 | - | |
Alistair Stokes | M | - | - | |
Alexandre LeBeaut | M | 66 | 6 years | |
Klaus-Peter Schwabe | M | 82 | - | |
Anne Beaufour | F | 60 | - | |
Yves Rambaud | M | 89 | - | |
René Merkt | M | 90 | - |
Statistics
Country | Connections | % of total |
---|---|---|
France | 69 | 69.00% |
United States | 27 | 27.00% |
Belgium | 5 | 5.00% |
Switzerland | 3 | 3.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Christophe Jean
- Personal Network